Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | KDR wild-type |
| Therapy | Elpamotide + Gemcitabine |
| Indication/Tumor Type | pancreatic cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| KDR wild-type | pancreatic cancer | sensitive | Elpamotide + Gemcitabine | Phase I | Actionable | In a Phase I trial, Elpamotide (VEGFR2-169), in combination with Gemzar (gemcitabine), achieved a disease control rate of 67% (12/18) and an improved overall survival time to 8.7 months in pancreatic cancer patients expressing the HLA-A*2402 version of the KDR (VEGFR2) wild-type allele (PMID: 19930156). | 19930156 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (19930156) | Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. | Full reference... |